Top Page
D.Western Therapeutics Institute
(4576)
D.Western Therapeutics Institute (4576) vs. iShares MSCI Japan ETF (EWJ)
D.Western Therapeutics Institute Business Overview & Revenue Model
D.Western Therapeutics Institute Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 421.06M | 387.62M | 471.58M | 428.36M | 448.10M | 414.42M |
| Gross Profit | 363.02M | 301.24M | 424.74M | 391.70M | 420.53M | 394.32M |
| EBITDA | -1.03B | -572.35M | -1.23B | -775.59M | -390.75M | -110.03M |
| Net Income | -1.09B | -632.09M | -1.29B | -812.41M | -429.69M | -149.00M |
Balance Sheet | ||||||
| Total Assets | 1.51B | 2.17B | 1.67B | 2.37B | 2.96B | 2.46B |
| Cash, Cash Equivalents and Short-Term Investments | 1.05B | 1.71B | 1.13B | 1.87B | 2.33B | 1.93B |
| Total Debt | 517.95M | 605.18M | 797.98M | 885.12M | 967.69M | 340.00M |
| Total Liabilities | 628.89M | 734.01M | 935.58M | 1.09B | 1.08B | 427.72M |
| Stockholders Equity | 884.57M | 1.44B | 733.87M | 1.28B | 1.86B | 2.01B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -496.54M | -1.31B | -601.76M | -364.58M | -179.21M |
| Operating Cash Flow | 0.00 | -493.79M | -1.30B | -586.82M | -354.77M | -176.31M |
| Investing Cash Flow | 0.00 | -2.45M | -10.01M | -15.25M | -139.89M | -111.15M |
| Financing Cash Flow | 0.00 | 1.08B | 567.63M | 134.47M | 867.30M | -104.46M |
D.Western Therapeutics Institute Technical Analysis
D.Western Therapeutics Institute Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | ¥17.82B | -54.84 | ― | ― | 1.24% | -33.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥59.40B | -18.92 | ― | ― | -82.33% | 47.73% | |
49 Neutral | ¥14.17B | -11.63 | ― | ― | -42.49% | -2.37% | |
48 Neutral | ¥176.20B | -46.79 | -636.97% | ― | ― | -12.69% | |
47 Neutral | ¥5.64B | -7.89 | -86.84% | ― | -9.39% | 24.12% | |
43 Neutral | ¥19.24B | -10.06 | ― | ― | ― | 11.34% |
D.Western Therapeutics Institute Corporate Events
D.Western Therapeutics Institute reported a 17.8% decline in net sales to ¥387 million for the year ended December 31, 2025, but significantly narrowed its net loss to ¥632 million from ¥1,290 million a year earlier, as operating cash outflows shrank and equity and net assets improved. The company ended the period with total assets of ¥2,169 million, a stronger equity ratio of 66.1%, cash and cash equivalents of ¥1,709 million, no dividends, and it forecasts further lower sales and a deeper loss in 2026, signaling continued investment-heavy operations and an extended path to profitability for shareholders.
Despite the improvement in capital position, D.Western Therapeutics Institute projects fiscal 2026 net sales of ¥300 million, down 22.6% year on year, and a wider net loss of ¥800 million, indicating expectations of higher costs or slower revenue recognition. The absence of dividends for 2025 and in the 2026 forecast underlines management’s focus on funding R&D and maintaining liquidity, which may weigh on short-term investor returns even as the balance sheet shows increased cash and strengthened equity.
The most recent analyst rating on (JP:4576) stock is a Hold with a Yen98.00 price target. To see the full list of analyst forecasts on D.Western Therapeutics Institute stock, see the JP:4576 Stock Forecast page.
D. Western Therapeutics Institute has released briefing materials for its fiscal year ending December 2025, outlining financial results, business progress, and forecasts for the next fiscal year. The document signals continued development of its therapeutic drug portfolio and provides stakeholders with an overview of performance trends and expectations for FY12/26, positioning the company within its specialty pharma niche despite limited disclosed detail.
The materials also include a reference business overview, indicating an effort to clarify the company’s operating model and strategic direction for investors. While specific figures are not provided in the excerpt, the structure of the briefing suggests a focus on linking financial performance with pipeline advancement and future outlook, underscoring the importance of ongoing R&D to its long-term growth strategy.
The most recent analyst rating on (JP:4576) stock is a Hold with a Yen98.00 price target. To see the full list of analyst forecasts on D.Western Therapeutics Institute stock, see the JP:4576 Stock Forecast page.
D.Western Therapeutics Institute reported a 17.8% decline in net sales to ¥387 million for the year ended December 31, 2025, although its net loss narrowed to ¥632 million from ¥1,290 million a year earlier. The company’s equity ratio improved significantly from 43.9% to 66.1%, supported by a stronger net asset position and an increase in cash and cash equivalents to ¥1,709 million.
Operating cash outflows shrank compared with the prior year while financing cash inflows rose, indicating continued reliance on external funding to support R&D activities. For 2026, the company projects a further drop in net sales to ¥300 million and a deeper loss of ¥800 million, and it has again ruled out dividends, underscoring an ongoing investment phase and limited near-term returns for shareholders.
The most recent analyst rating on (JP:4576) stock is a Hold with a Yen98.00 price target. To see the full list of analyst forecasts on D.Western Therapeutics Institute stock, see the JP:4576 Stock Forecast page.
D. Western Therapeutics Institute has released briefing materials for its fiscal year ending December 2025, outlining financial results, business progress, and its forecast for fiscal 2026. The document signals continued efforts to communicate performance and strategic direction, providing stakeholders with an overview of current operations and expectations for the coming year, although specific financial figures and project details are not disclosed in this summary.
The most recent analyst rating on (JP:4576) stock is a Hold with a Yen98.00 price target. To see the full list of analyst forecasts on D.Western Therapeutics Institute stock, see the JP:4576 Stock Forecast page.
D. Western Therapeutics Institute announced that its partner Kowa has begun sales in Singapore of GLA-ALPHA Combination Ophthalmic Solution, a fixed-dose eye drop that combines the company’s in-house discovered Rho-kinase inhibitor ripasudil hydrochloride hydrate with brimonidine tartrate for the treatment of glaucoma and ocular hypertension. The product, already launched in Japan, Thailand and Malaysia, offers a novel mechanism versus existing combination therapies, is expected to support better intraocular pressure control and adherence for patients using multiple eye medications, and will generate royalty income for DWTI, with the financial impact to be incorporated into its earnings forecast for the year ending December 2026.
The most recent analyst rating on (JP:4576) stock is a Hold with a Yen98.00 price target. To see the full list of analyst forecasts on D.Western Therapeutics Institute stock, see the JP:4576 Stock Forecast page.
D. Western Therapeutics Institute, Inc. has announced the launch of its new glaucoma and ocular hypertension treatment, ‘GLA-ALPHA® Combination Ophthalmic Solution,’ in Malaysia through its partner Kowa Co., Ltd. This product, which combines ripasudil hydrochloride hydrate and brimonidine tartrate, offers a novel treatment option with a unique mechanism of action, potentially improving patient adherence to multiple ophthalmic medications. The drug has been successfully marketed in Japan and Thailand, with plans for further expansion in Singapore and beyond. Although the launch is expected to enhance treatment options in Malaysia, it will have a minimal impact on the company’s current fiscal year earnings.
The most recent analyst rating on (JP:4576) stock is a Hold with a Yen98.00 price target. To see the full list of analyst forecasts on D.Western Therapeutics Institute stock, see the JP:4576 Stock Forecast page.
D. Western Therapeutics Institute has announced the completion of the observation period for subjects in the global phase III clinical study of their drug K-321, developed to treat Fuchs endothelial corneal dystrophy. This milestone marks a significant step forward in the drug’s development, as the data collected will now be analyzed to assess the drug’s efficacy and safety compared to a placebo. The company, in collaboration with Kowa Company, Ltd., aims to provide new treatment options for patients suffering from this condition, which currently has limited therapeutic options. The announcement does not affect the company’s earnings forecast for the fiscal year ending December 2025.
The most recent analyst rating on (JP:4576) stock is a Hold with a Yen98.00 price target. To see the full list of analyst forecasts on D.Western Therapeutics Institute stock, see the JP:4576 Stock Forecast page.
D.Western Therapeutics Institute, Inc. has completed the final observation phase of its domestic phase II clinical trial for the regenerative medical cell product DWR-2206, developed in collaboration with ActualEyes Inc. The trial, aimed at evaluating the safety and efficacy of DWR-2206 for treating bullous keratopathy, reported no critical adverse events and noted improvements in visual acuity. The company is now preparing for a phase III clinical trial scheduled for fiscal 2026, marking a significant milestone in the development of this innovative treatment. This progress aligns with the company’s plans and is not expected to impact the earnings forecast for the fiscal year ending December 2025.
The most recent analyst rating on (JP:4576) stock is a Hold with a Yen98.00 price target. To see the full list of analyst forecasts on D.Western Therapeutics Institute stock, see the JP:4576 Stock Forecast page.